AI Tool Could Speed Discovery of New Cancer Drug Targets
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy (GAIN-BCG)
Adaptive Radiation Therapy for Men with Intermediate- or High-Risk Prostate Cancer (DE-CART)
Dana-Farber’s Dr. Toni Choueiri Elected to the Association of American Physicians
Dana-Farber Phase 1 Study Explores Toxicity Reduction in Combination of Trastuzumab Deruxtecan and Olaparib in Advanced HER2-Expressing Malignancies
Stuart Orkin Awarded Breakthrough Prize in Life Sciences
Dana-Farber Researchers Presented More Than 50 Research Studies at American Association for Cancer Research Annual Meeting 2026
Immune Activity Shift a Key Early Step in Breast Cancer Formation
Dana-Farber Researchers Receive AACR 2026 Scientific Achievement Awards
The Next Wave of Immune Cell Therapy
Dana-Farber Chair of Pathology, Dr. Kathleen Burns, Elected as Fellow of the American Association for the Advancement of Science
Dana-Farber Team Develops Open-Access Predictive Tool to Improve Monitoring of Smoldering Multiple Myeloma
Dana Farber/Boston Children’s Researchers Uncover Distinct Tumor “neighborhoods” with Each Cell Subtype Playing a Specific Role, in Aggressive Childhood Brain Cancer
When Small Cell Lung Cancer Hides from Immune Cells, Blood Vessels May Hold the Key
The Gene Fixer
Showing 1 - 15 of 1032 results
Previous| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ...69 |Next
Cancer
Cardiology
Gastroenterology
Neurology
OBGYN
Orthopedics
Pediatrics
BroadcastMed News
Dermatology
Diabetes & Endocrinology
Infectious Diseases
Ophthalmology
Optometry
Otolaryngology
Pulmonology
Surgery
Urology
About
Solutions
Resources
Contact
person Sign In / Create Account
